| Literature DB >> 30341118 |
Toshio Nakadate1, Yuko Yamano1, Takenori Yamauchi1, Shigeko Okubo1, Daichi Nagashima1.
Abstract
BACKGROUND: Little epidemiological evidence exists regarding the chronic respiratory effects of inhaled powdered toner exposure in humans, although several case reports have suggested the existence of lung disorders that might be related to exposure to toner dust.Entities:
Keywords: epidemiology; respiratory medicine (see thoracic medicine)
Mesh:
Substances:
Year: 2018 PMID: 30341118 PMCID: PMC6196812 DOI: 10.1136/bmjopen-2018-022049
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1The number of subjects analysed based on the inclusion criteria of this study.
Background characteristics of the subjects according to the exposure category
| Characteristics | Category of exposure condition | ||||||
| Control | Exposed | P values† | |||||
| Total | TPD | DDM | MTN | RCL | |||
| Number surveyed | 217 | 477 | 175 | 145 | 150 | 7 | |
| Sex (M/F) | 205/12 | 461/16 | 167/8 | 141/4 | 149/1 | 3-Apr | 0.18 |
| Age (years) | 39.1 (8.2) | 34.1 (8.1) | 32.9 (10.3) | 35.4 (6.5) | 34.2 (6.3) | 32.4 (7.6) | <0.0001 |
| Height (cm) | 170.1 (6.6) | 170.3 (6.4) | 169.0 (6.1 | 171.3 (6.4) | 171.4 (6.4) | 161.5 (6.8) | 0.63 |
| BMI (kg/m2) | 23.0 (3.1) | 23.0 (3.7) | 23.2 (4.6) | 22.4 (2.6) | 23.4 (3.2) | 19.9 (1.5) | 0.999 |
| Smoking habit‡ | 0.026 | ||||||
| Never | 70(32) | 150(31) | 38(22) | 69(48) | 38(25) | 5 (71) | |
| Former | 47(22) | 67(14) | 17(10) | 26(18) | 24(16) | 0 | |
| Current | 100(46) | 260(55) | 120(68) | 50(34) | 88(59) | 2 (29) | |
| Personal exposure (mg/m3) | - | ||||||
| Number of samples | 2042 | 1751 | 81 | 88 | 122 | ||
| Total dust | |||||||
| 10th percentile | 0.08 | 0.09 | 0.04 | 0.07 | 0.51 | ||
| Median | 0.49 | 0.5 | 0.08 | 0.17 | 1.46 | ||
| 90th percentile | 2.38 | 2.14 | 0.38 | 0.8 | 5.6 | ||
| Respirable dust | |||||||
| 10th percentile | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 | ||
| Median | 0.05 | 0.09 | 0.03 | 0.03 | 0.04 | ||
| 90th percentile | 0.36 | 0.35 | 0.04 | 0.15 | 0.64 | ||
Values are presented as the number of subjects for sex and smoking habit and the arithmetic mean (SD) for age, height and BMI at the baseline survey.
†Probability under the hypothesis that there are no differences between the control group and the exposed group as a whole.
‡Percentage of column total in parentheses.
BMI, body mass index; DDM, machine design and development; MTN, maintenance; RCL, recycling; TPD, toner production.
Figure 2The exposure levels of toner-handling workers by year of measurement estimated by personal exposure measurements. The values are presented as the median and the 10th and 90th percentiles (%ile) for personal exposure measurement data.
The comparison of the baseline status in select biomedical indices at the point of the first examination for each subject between the exposed subjects as a whole and the controls
| Biomedical indices | Univariate analysis | P values* | Multivariate analysis | ||
| Prevalence (%) | Logistic regression model | ||||
| Exposed | Controls | OR† | 95% CI† | ||
| Respiratory symptoms‡ | |||||
| Cough #1 (7A) | 19.4 | 14.8 | 0.14 | 1.35 | (0.85 to 2.14) |
| Cough #2 (7B) | 14.8 | 11.1 | 0.19 | 1.41 | (0.84 to 2.37) |
| Chronic cough (7E) | 5.5 | 4.2 | 0.46 | 1.6 | (0.70 to 3.64) |
| Phlegm #1 (8A) | 23.7 | 20.4 | 0.34 | 1.23 | (0.81 to 1.87) |
| Phlegm #2 (8B) | 13.5 | 10.7 | 0.29 | 1.45 | (0.85 to 2.48) |
| Chronic phlegm (8E) | 8.9 | 4.2 | 0.03 | 2.62 | (1.20 to 5.70) |
| Exacerbation (9A) | 10.5 | 7 | 0.14 | 1.56 | (0.84 to 2.91) |
| Wheeze #1 (10A1) | 9.5 | 5.6 | 0.09 | 1.51 | (0.76 to 2.99) |
| Wheeze #2§ (10A2) | 2.7 | 0 | 0.01 | – | – |
| Chronic wheeze (10A3) | 0 | 0 | – | – | – |
| Breathlessness #1 (13A) | 9.7 | 11.6 | 0.45 | 1 | (0.58 to 1.73) |
| Breathlessness #2§ (13B) | 2.2 | 1.4 | 0.76 | 2.27 | (0.58 to 8.89) |
| Breathlessness #3§ (13C) | 0.4 | 0.9 | 0.59 | 0.96 | (0.13 to 7.20) |
| Biomarker abnormality | |||||
| CRP | 12 | 6 | 0.02 | 2.02 | (1.05 to 3.88) |
| IgE | 31.7 | 20.8 | 0.003 | 1.66 | (1.12 to 2.48) |
| 8OHdG§ | 1.1 | 1.8 | 0.47 | 0.68 | (0.17 to 2.78) |
| KL6§ | 0.4 | 0 | 1 | - | - |
| SPD | 3.2 | 3.4 | 0.89 | 0.91 | (0.35 to 2.37) |
| Reduced pulmonary function | |||||
| FVC | 6.5 | 6 | 0.76 | 1 | (0.49 to 2.00) |
| FEV1 | 6.1 | 2.8 | 0.06 | 2.09 | (0.83 to 5.27) |
| FEV1/FVC§ | 2.1 | 5.1 | 0.03 | 0.44 | (0.18 to 1.09) |
| Chest X-ray findings | |||||
| Fibrotic change ≥1/1 | 0 | 0 | 1 | – | – |
| Non-specific findings | 3.4 | 1.8 | 0.27 | 2.47 | (0.78 to 7.81) |
The figures in the column of prevalence represent the proportion of subjects with symptoms or positive findings in each index. The results of multivariate analyses were adjusted for the age and smoking status of the subjects. Body mass index was also used as an adjustment factor in the case of CRP.
*Probability under the hypothesis that there are no differences between the control group and exposed group as a whole examined by the χ2 test or Fisher’s exact probability method.
†OR and its 95% CIs of the exposed group to the control group, regarding the positive findings at the baseline survey.
‡The ATS-DLD-78A questionnaire code is shown in the parentheses.
§Fisher’s exact probability method was applied.
#Grade of symptom severity: cough #1 and phlegm #1: usually having the symptom; cough #2 and phlegm #2: 4–6 times a day on 4 or more days a week; wheeze #1: when having a cold; wheeze #2: occasionally apart from cold; breathlessness #1: when hurrying on the level or walking up a slight hill; breathlessness #2: having to walk slower than people your age on the level; breathlessness #3: having to stop for breath when walking at your own pace.
8OHdG, 8-hydrovy deoxy guanosine; ATS, American Thoracic Society; CRP, C reactive protein; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; IgE, immunoglobulin E; KL6, sialylated carbohydrate antigen KL-6; SPD, surfactant protein D.
A comparison of the cumulative frequency of incidence in select biomedical indices associated with lung fibrotic changes that newly emerged during the follow-up period
| Univariate analysis | P values* | Multivariate analysis | |||||
| Incidence | Logistic regression model | ||||||
| Total | Total | TPD | DDM | MTN | |||
| Exposed | Controls | OR (95% CI)† | OR (95% CI)† | OR (95% CI)† | OR (95% CI)† | ||
| Respiratory symptoms‡ | |||||||
| Chronic cough (7E) | 11.3 | 6.3 | 0.04 | 2.26 (1.13 to 4.53) | 1.88 (0.82 to 4.31) | 2.70 (1.21 to 5.99) | 2.31 (1.01 to 5.25) |
| Chronic phlegm (8E) | 14 | 9.6 | 0.12 | 1.6 (0.91 to 2.83) | 1.46 (0.74 to 2.88) | 1.65 (0.81 to 3.37) | 1.68 (0.83 to 3.40) |
| Breathlessness #2 (13B) | 6 | 4.7 | 0.48 | 1.69 (0.73 to 3.94) | 1.51 (0.54 to 4.19) | 0.94 (0.27 to 3.25) | 2.62 (1.00 to 6.87) |
| Serum biomarkers | |||||||
| KL6§ | 2.1 | 1.8 | 1 | 1.27 (0.38 to 4.29) | 2.09 (0.54 to 8.05) | 0.44 (0.05 to 4.09) | 1.25 (0.26 to 5.94) |
| SPD | 2.4 | 2.4 | 1 | 1.06 (0.34 to 3.28) | 0.87 (0.21 to 3.54) | 1.62 (0.40 to 6.48) | 0.94 (0.21 to 4.24) |
| Pulmonary function | |||||||
| FVC | 15.3 | 13.2 | 0.5 | 1.22 (0.73 to 2.05) | 2.60 (1.44 to 4.71) | 0.54 (0.24 to 1.21) | 0.84 (0.42 to 1.68) |
| FEV1 | 11.4 | 8.5 | 0.26 | 1.38 (0.76 to 2.49) | 2.43 (1.24 to 4.76) | 0.68 (0.27 to 1.69) | 1.19 (0.55 to 2.57) |
| FEV1/FVC | 9.9 | 6.8 | 0.2 | 1.59 (0.81 to 3.09) | 1.88 (0.87 to 4.09) | 1.16 (0.48 to 2.85) | 1.72 (0.77 to 3.85) |
| Chest X- ray | |||||||
| Non-specific findings | 5.6 | 5.2 | 0.8 | 1.39 (0.65 to 2.97) | 1.38 (0.53 to 3.59) | 1.75 (0.70 to 4.37) | 0.98 (0.34 to 2.80) |
The figures in the column of incidence represent the proportion of subjects starting to show symptoms or positive findings during the follow-up period among those who did not have the symptom or positive finding at baseline. The results of multivariate analyses were adjusted for the age and smoking status of the subjects.
*Probability under the hypothesis that there are no differences between the control group and exposed group as a whole examined by the χ2 test or Fisher’s exact probability method.
†OR and its 95% CIs of the exposed group to the control group, regarding the newly emerging abnormalities of biomedical indices.
‡The ATS-DLD-78A questionnaire code is shown in the parentheses.
§Fisher’s exact probability method was applied.
#Grade of the severity of the symptom.
ATS, American Thoracic Society; DDM, machine design and development; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; KL6, sialylated carbohydrate antigen KL-6; MTN, maintenance; RCL, recycling; SPD, surfactant protein D; TPD, toner production.
Annual decline in spirometric indices according to exposure category
| Spirometric indices | Category of exposure condition (number of subjects) | |||||||
| Control | Exposed | Statistical test of the mean values* | ||||||
| (n=217) | Total | TPD | DDM | MTN | RCL | P values | ||
| (n=477) | (n=175) | (n=145) | (n=150) | (n=7) | Unadjusted | Adjusted† | ||
| ΔFVC/HT2 (mL/m2) | −6.2 (21.4) | −4.0 (19.1) | −0.7 (25.8) | −2.5 (12.5) | −9.0 (14.3) | −5.8 (13.3) | 0.19 | 0.5 |
| ΔFEV1/HT2 (mL/m2) | −8.8 (16.3) | −7.5 (13.9) | −6.5 (16.3) | −7.3 (10.7) | −9.0 (12.5) | −6.7 (32.6) | 0.33 | 0.3 |
Values are the arithmetic means and SD at the point of baseline survey.
†*Comparison between the control and the exposed as a whole.
†Adjusted for age, sex and smoking habit at the baseline.
DDM, machine design and development; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; H2, height-squared; MTN, maintenance; RCL, recycling; TPD, toner production.
Independent contribution of confounding factors in the multivariate analyses of biomedical indices
| Smoking | Age | BMI | |||
| Prevalence* | Incidence† | Prevalence* | Incidence† | Prevalence* | |
| OR (95% CI)‡ | OR (95% CI)‡ | OR (95%Cis)‡ | OR (95% CI)‡ | OR (95% CI)‡ | |
| Cough #1 (7A)§ | 1.68 (1.12 to 2.51) | ||||
| Cough #2 (7B)§ | 1.62 (1.03 to 2.54) | ||||
| Chronic cough (7E)§ | 3.34 (1.49 to 7.48) | 1.63 (1.08 to 2.45) | |||
| Phlegm #1 (8A)§ | 2.38 (1.63 to 3.47) | ||||
| Phlegm #2 (8B)§ | 2.62 (1.60 to 4.29) | 1.38 (1.05 to 1.82) | |||
| Chronic phlegm (8C)§ | 3.69 (1.85 to 7.35) | 1.80 (1.10 to 2.96) | 1.53 (1.08 to 2.16) | ||
| Breathlessness #1 (13A)§ | 1.59 (1.17 to 2.16) | ||||
| Breathlessness #2†(13B)§ | 2.64 (1.36 to 5.12) | ||||
| Breathlessness #3†(13C)§ | 5.62 (1.51 to 20.85) | ||||
| CRP abnormality | 1.32 (1.17 to 1.49) | ||||
| SPD abnormality | 4.10 (1.15 to 14.58) | ||||
| Reduced FVC | 3.13 (1.09 to 8.97) | ||||
| Reduced FEV1 | 3.82 (1.38 to 10.58) | ||||
| Reduced FEV1/FVC | 3.92 (1.20 to 12.87) | 2.11 (1.27 to 3.52) | |||
| Non-specific X-ray | 1.59 (1.06 to 2.38) | ||||
| Findings | |||||
Values are presented as the OR (95% CI) estimated using the logistic regression models shown in tables 3 and 4. Only statistically significant results are shown.
*An analysis of the prevalence at baseline.
†An analysis of the new incidence during the follow-up observation.
‡OR and its 95% CI of the exposed group to the control group, regarding the prevalence and incidence of biomedical indices.
§The ATS-DLD-78A questionnaire code is shown in the parentheses.
#Grade of the severity of the symptom.
ATS, American Thoracic Society; CRP, C reactive protein; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; SPD, surfactant protein D.